Diabesity is a term used to describe the combined adverse health effects of obesity and
diabetes mellitus. The worldwide dual epidemic of obesity and type 2 diabetes is an …

Abstract Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide
and a major economic burden. The prevalence of T2DM is rising, suggesting more effective …

Patients with type 2 diabetes (T2DM) have a substantial risk of develo** cardiovascular
disease. The strong connection between the severity of hyperglycaemia, metabolic changes …

Autonomic nervous system (ANS) imbalance manifesting as cardiac autonomic neuropathy
in the diabetic population is an important predictor of cardiovascular events. Symptoms and …

While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart
rate (HR), it is insufficiently recognized that the extent varies greatly between the various …

Aims Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat
type 2 diabetes and obesity. Albeit cardiovascular outcomes generally improve, treatment …

Aim The cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists
(GLP‐1RAs) extend beyond weight reduction and glycaemic control. One possible …

Background Incretin-based therapies are used in the treatment of type 2 diabetes mellitus
(T2DM) and obesity. We investigated the changes in arterial stiffness and left ventricular (LV) …

Background Macrophages play a pivotal role in atherosclerotic plaque development. Recent
evidence has suggested the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide …

Objective: There is substantial interest in how GLP-1RA (glucagon-like peptide-1 receptor
agonists) and SGLT2 (sodium-glucose cotransporter 2) inhibitors reduce cardiovascular and …